Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

TABRECTA FILM-COATED TABLET 150MG [SIN16350P]

Active ingredients: TABRECTA FILM-COATED TABLET 150MG

View product's general information
Last updated 24 April 2026

Product Info

TABRECTA FILM-COATED TABLET 150MG

[SIN16350P]

Product information

Active Ingredient and Strength

CAPMATINIB DIHYDROCHLORIDE MONOHYDRATE EQV CAPMATINIB - 150 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

LEK D.D. (PRIMARY AND SECONDARY PACKAGER) - SLOVENIA
NOVARTIS PHARMA PRODUKTIONS GMBH - GERMANY
NOVARTIS PHARMACEUTICALS S.R.L. - ROMANIA

Registration Number

SIN16350P

Licence Holder

NOVARTIS (SINGAPORE) PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

L01EX17

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

3 Indications

Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation.

Dosing

4 Dosage regimen and administration

Patient selection

Patients should be selected for treatment with Tabrecta based on the presence of a MET exon 14 skipping mutation in tumor or plasma specimens using a validated test. If a MET exon 14 skipping mutation is not detected in a plasma specimen, tumor tissue should be tested if feasible.

Dosage regimen

General target population

The recommended dose of Tabrecta is 400 mg orally twice daily with or without food (see section 11 Clinical pharmacology – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Treatment duration

Treatment should be continued based on individual safety and tolerability and as long as the patient is deriving clinical benefit from therapy.

Dose modifications for adverse drug reactions

The recommended dose reduction schedule for the management of adverse drug reactions (ADRs) based on individual safety and tolerability is listed in Table 4-1.

Tabrecta Dosage Table 4-1



Tabrecta should be permanently discontinued in patients unable to tolerate 200 mg orally twice daily.

Recommendations for dose modifications of Tabrecta for ADRs are provided in Table 4-2.

Tabrecta Dosage Table 4-2



Special populations

Renal impairment

No dose adjustment is necessary in patients with mild or moderate renal impairment based on population pharmacokinetic evaluations; Tabrecta has not been studied in patients with severe renal impairment (see section 11 Clinical pharmacology – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Hepatic impairment

No dose adjustment is necessary in patients with mild, moderate, or severe hepatic impairment (see section 11 Clinical pharmacology – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Pediatric patients (below 18 years of age)

The safety and efficacy of Tabrecta in pediatric patients have not been established.

Geriatric patients (65 years of age or older)

No dose adjustment is necessary in patients 65 years of age or older.

Method of administration

Tabrecta should be taken orally twice daily with or without food. The tablets should be swallowed whole and should not be broken, chewed, or crushed.

If a dose of Tabrecta is missed or vomiting occurs, the patient should not make up the dose, but take the next dose at the scheduled time.

Contraindications

5 Contraindications

None.